MedTrace Logo

Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide

NCT00441909 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-03-05

No results posted yet for this study

Summary

Vaginal microbicides are compounds that may protect women from HIV and other sexually transmitted infections (STIs). This study will determine the safety of the microbicide UC-781 by comparing the effects of keeping the microbicide in the vagina for different lengths of time.

Conditions

  • HIV Infections

Interventions

DRUG

UC-781

0.1% UC-781 Vaginal Gel

DRUG

UC-781 placebo

Vaginal Gel Placebo

Sponsors & Collaborators

  • CONRAD

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Sharon L. Hillier, PhD · University of Pittsburgh

  • Harold C. Wiesenfeld, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00441909 on ClinicalTrials.gov